Home
Science and IP
Investors
Our Team
Events
News Releases
Contact
NASDAQ: CMND
FWB: CWY0
News Releases
Below are the latest News Releases for Clearmind Medicine Inc.
10
May
2022
Clearmind Medicine Inc. and SciSparc Ltd., Collaboration Yields New Provisional Patent Application for Psychedelic Combination...
Read More
9
May
2022
Clearmind Strengthens its Scientific Advisory Board With Substance Abuse and Mental Health Professionals
Read More
17
March
2022
Clearmind Medicine Announces Positive Results on CMND-100 trials
Read More
8
March
2022
Clearmind Medicine, SciSparc Launch a Psychedelic Pharma Collaboration
Read More
17
February
2022
Clearmind Medicine to Host a "Psychedelics for Alcoholism" Event for Investors on February 23
Read More
9
February
2022
Clearmind Medicine announces Share-Based Compensation Plan
Read More
8
February
2022
Clearmind Medicine Secures CAD$1.6 Million in Private Placement
Read More
31
January
2022
Clearmind Medicine Now Fully Eligible for Settlement through the Depository Trust Company (“DTC”)
Read More
28
January
2022
Clearmind Medicine Partners with Dr. Gabor Maté to Discuss Alcohol Use Disorder and Trauma in a Special Virtual Event on Feb 3
Read More
19
January
2022
Clearmind Medicine to Host “Psychedelics for Alcoholism: From Molecule to Medicine” Virtual Event on January 26
Read More
13
January
2022
Mark Haden, Clearmind Medicine's VP of Business Development Presented at The Canadian Psychedelics Association Event
Read More
11
January
2022
Clearmind Medicine Strengthens Presence in North America with New Senior Appointments
Read More
24
November
2021
Clearmind Medicine Launches Study for Binge Eating with The Hebrew University Using its Proprietary MEAI Compound
Read More
22
November
2021
Clearmind Medicine to Pursue Dual Listing on Nasdaq
Read More
18
November
2021
Clearmind Medicine Engages Bar-Ilan University to Evaluate Anti-Addictive Properties of Clearmind's Proprietary MEAI Compound
Read More
Previous
Next
